secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001437749-26-005733
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M
--------------------------------------------------------------------------------

- Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).
- Net income Q4 $23.0M; full year $447.2M including $339.8M non-recurring deferred tax asset benefit.
- 2026 guidance: total global revenue $875-900M; BRIUMVI US net $825-850M; Q1 2026 target $185-190M.
- Completed $100M share repurchase (3.5M shares at avg $28.55); new $100M buyback authorized.
- Pipeline milestones: ENHANCE IV data mid-2026; subcutaneous ublituximab data year-end 2026/1Q 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/0001437749-26-005733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/tgtx20251112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-005733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer